Perkins Capital Management Inc buys $1,423,760 stake in BioTelemetry (BEAT)

BioTelemetry (BEAT) : Perkins Capital Management Inc scooped up 1,200 additional shares in BioTelemetry during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 18, 2016. The investment management firm now holds a total of 120,250 shares of BioTelemetry which is valued at $1,423,760.BioTelemetry makes up approximately 1.70% of Perkins Capital Management Inc’s portfolio.

BioTelemetry opened for trading at $11.87 and hit $11.93 on the upside on Friday, eventually ending the session at $11.84, with a gain of 0.17% or 0.02 points. The heightened volatility saw the trading volume jump to 93,924 shares. Company has a market cap of $324 M.

Other Hedge Funds, Including , Palo Capital added BEAT to its portfolio by purchasing 14,378 company shares during the most recent quarter which is valued at $170,236. BioTelemetry makes up approx 0.13% of Palo Capital’s portfolio.Falcon Point Capital boosted its stake in BEAT in the latest quarter, The investment management firm added 70,371 additional shares and now holds a total of 132,923 shares of BioTelemetry which is valued at $1,547,224. BioTelemetry makes up approx 0.27% of Falcon Point Capital’s portfolio.Simplex Trading reduced its stake in BEAT by selling 572 shares or 43.24% in the most recent quarter. The Hedge Fund company now holds 751 shares of BEAT which is valued at $8,742.Franklin Street Advisors Inc Nc boosted its stake in BEAT in the latest quarter, The investment management firm added 600 additional shares and now holds a total of 22,700 shares of BioTelemetry which is valued at $264,228. BioTelemetry makes up approx 0.05% of Franklin Street Advisors Inc Nc’s portfolio.

On the company’s financial health, BioTelemetry reported $0.10 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on Feb 17, 2016. Analyst had a consensus of $0.11. The company had revenue of $46.70 million for the quarter, compared to analysts expectations of $45.89 million. The company’s revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.05 EPS.

Leave a Reply

BioTelemetry - Is it time to Sell?

Top Brokerage Firms are advising their investors on BioTelemetry. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.